DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20162271

An evaluation of quality of life of skin cancer patients after surgery using dermatology life quality index tool

Shailendra Kumar Jain, Preeti Jain, Abhishek Singh, Shewtank Goel, Pooja Goyal, Rakesh Tank

Abstract


Background: Quality of life (QOL) has been identified as an important outcome in cancer researches yet the most common malignancy among humans, non-melanoma skin cancer (NMSC), but poorly studied. Aim of the study was to analyze the quality of life of non-melanoma skin cancer patients after surgery using dermatology life quality index inventory (DLQI).

Methods: Retrospective cohort of patients operated for non-melanoma skin cancer in last 2 years and paid postoperative 4-month visit formed the study population. Inclusion criteria consisted of subjects operated for non-melanoma skin cancer and paid follow up visits having sufficient physical and mental capacity. Fifty-six subjects fulfilled the selection criteria laid down thus included in this study. Study tools were records of patients, which were obtained from medical records section. If any more information was required, study subjects were contacted.

Results: Out of total 56 study subjects, Basal cell carcinomas were found in 91.1% (n=51); squamous cell carcinomas were detected in 7.2% (n=4). Single location wise more lesions were located on the nose 22.1% (n=15) and forehead 17.6% (12). For most patients (75%), the lesion had not been previously treated. 58.9% subjects did not have any other associated co-morbid condition. Lower mean values were observed post-operative i.e. lower DLQI scores were recorded 4 months after surgery in our study which indicates that adverse effects were not very prominent thus preserving quality of life post operatively. Paired sample t-tests revealed a significant effect on DLQI item 1 (p=0.008), item 2 (p=0.043), and item 4 (p=0.003), with scores decreasing (improving QOL) after treatment. The change in total DLQI score demonstrated a trend toward significance, with overall QOL improving after treatment (p=0.024).

Conclusions: Previously commonly employed dermatological Quality of life tools demonstrated minimal handicap at initial diagnosis and little change after treatment of nonmelanoma skin cancer. Development of disease-specific instrument is warranted to explore the disease process.

 


Keywords


Evaluation, Quality of life, Skin cancer, Patients, Surgery

Full Text:

PDF

References


Panda S. Non melanoma skin cancer in India: current scenario. Indian J Dermatol. 2010;55(4): 373-8.

Meibodi NT, Maleki M, Javidi Z, Nahidi Y. Clinicopathological evaluation of radiation induced basal cell carcinoma. Indian J Dermatol. 2008;53:137-9.

Rhee JS, Matthews BA, Neuburg M, Logan BR, Burzynski M, Nattinger AB. The skin cancer index: clinical responsiveness and predictors of quality of life. Laryngoscope. 2007;117:399-405.

US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (US), Center for Biologics Evaluation and Research (US), Center for Devices and Radiological Health (US). Guidance for industry patient-reported outcome measures: use in medical product development to support labelling claims. 2009.

Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5:105-10.

Potocka A, Turczyn-Jabłońska K, Kiec-Swierczynska M. Self-image and quality of life of dermatology patients. Int J Occup Med Environ Health. 2008;21:309-17.

Derogatis LR, Morrow GR, Fetting J, Penman D, Piasetsky S, Schmale AM. The prevalence of psychiatric disorders among cancer patients. JAMA. 1983;249:751-7.

Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. Psychooncology 2001;10:19-28.

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-6.

Blackford S, Roberts D, Salek MS, Finlay A. Basal cell carcinomas cause little handicap. Qual Life Res. 1996;5:191-4.

Hahn HB, Melfi CA, Chuang TY, Lewis CW, Gonin R, Hanna MP. Use of the Dermatology Life Quality Index (DLQI) in a midwestern US urban clinic. J Am Acad Dermatol. 2001;45:44-8.

Coates E, Chee SN, Lowe PM. Dermatological challenges in solid organ transplant recipients: the first 18 months of a dedicated transplant dermatology database. Australas J Dermatol. 2013;54(S2):36.

Chen SC, Bayoumi AM, Soon SL et al. A catalog of dermatology utilities: a measure of the burden of skin diseases. J. Investig. Dermatol. Symp. Proc. 2004;9:160-8.

Essers B, Nieman F, Prins M, Smeets N, Neumann H. Perceptions of facial aes-thetics in surgical patients with basal cell carcinoma. J Eur Acad Dermatol Venereol. 2007;21:1209-14.

Chren MM. The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin. 2012;30:231-6.

Trask PC, Paterson AG, Hayasaka S, Dunn RL, Riba M, Johnson T. Psychosocial characteristics of individuals with non-stage IV melanoma. J Clin Oncol. 2001;19:2844-50.

Rhee JS, Loberiza FR, Matthews BA, Neuburg M, Smith TL, Burzynski M. Quality of life assessment in nonmelanoma cervicofacial skin cancer. Laryngoscope. 2003;113:215-20.

Rhee JS, Matthews BA, Neuburg M, Smith TL, Burzynski M, Nattinger AB. Skin cancer and quality of life: assessment with the Dermatology Life Quality Index. Dermatol Surg. 2004;30(4 Pt 1): 525-9.